Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
73.00    -0.50 (-0.68%)
Bid:
72.00
Ask:
74.00
Spread: 2.00 (2.778%)
Market Cap: £342.04m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Directorate Change

7 Jul 2006 16:07

Readybuy PLC07 July 2006 Readybuy plc Board appointments Readybuy plc (the "Company") announces the appointment of Daron Lee asnon-executive chairman and Professor Alastair Smith as a non-executive directorof the Company. The Company also announces the resignations of Colin Davies andKeith Salisbury with immediate effect. Daron Ross Lee (aged 39), commenced his career with stockbrokers Ashworth Sons &Barratt in 1987 before pursuing other opportunities within the family business.He then returned to stockbroking with WH Ireland Limited before establishingProquote Limited ("Proquote"), a business engaged in the provision of on-linestockmarket data and company information. Proquote was sold in February 2003 tothe London Stock Exchange plc and Daron remained with Proquote as its managingdirector until the end of 2004. Since then Daron has pursued a number ofpersonal business interests. Daron Lee is interested in 15,000,000 ordinary shares of 0.1p each in thecapital of the Company ("Ordinary Shares"), representing 12.06 per cent. of theissued ordinary share capital of the Company, and warrants to subscribe for7,500,000 Ordinary Shares. Professor David Alastair Maclaughlin Smith (aged 39), is a director of AvactaLimited, Avacta Analytical Limited and TT123 Limited. During the past fiveyears he has also been a director of Hebden Lodge Hotel Company Limited. He hasa degree and PhD in Physics from Manchester University and, after working in theUS for a period, took up a position at Leeds University in 1995. Alastair hasspent the last 10 years developing new biophysical technologies and applyingthem to problems in structural molecular biology. At the age of 38 he wasawarded a Chair of Molecular Biophysics for this work and he also holds theDirectorship of the Institute of Molecular Biophysics at Leeds University. There are no other disclosures required under Schedule Two (g) of the AIM rules. For further information please contact: Daron Lee, Readybuy plc Tel: 07802 88 89 11David Youngman, WH Ireland Limited Tel: 0161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Sep 20177:00 amRNSNotice of Results
21st Aug 201712:00 pmRNSDirector/PDMR Shareholding
7th Aug 20177:00 amRNSTrading Update
31st Jul 201712:00 pmRNSIssue of Equity
28th Jul 20171:15 pmRNSDirector/PDMR Shareholding
5th Jul 20177:00 amRNSDirector Dealing and Issue of Equity
4th Jul 20177:00 amRNSManchester ShareSoc Growth Company Seminar
5th Jun 20177:00 amRNSShareSoc Growth Company Seminar
1st Jun 20178:56 amRNSIssue of Equity
22nd May 20177:00 amRNS2 Biotech's Licence Affimers for Research Use
10th May 20177:00 amRNSKey Affimer Patent To Be Granted in China
8th May 20171:21 pmRNSHardman Research: De-risking Moderna's partnership
5th May 20177:00 amRNSPresenting at the Hardman Private Investor Forum
2nd May 20177:00 amRNSAvacta to Present at BioTrinity 2017
24th Apr 20177:00 amRNSDiagnostics firm take rights to several Affimers
19th Apr 20177:00 amRNSAvacta to Present at the Shares Spotlight Evening
12th Apr 20177:15 amRNSHardman Research: Another important box ticked
6th Apr 20172:23 pmRNSHolding(s) in Company
6th Apr 20172:23 pmRNSHolding(s) in Company
6th Apr 201710:22 amRNSDirector/PDMR Shareholding
3rd Apr 20177:00 amRNSInterim Results for the Period Ended 31 Jan 2017
3rd Apr 20177:00 amRNSResults of Immunogenicity Study with Human Samples
31st Mar 20179:31 amRNSAvacta Presents at Investor Evening Hosted by TPI
31st Mar 20177:00 amRNSLondon Growth and Innovation Forum Presentation
22nd Mar 20179:00 amRNSAvacta to present at the UK Investor Show
21st Mar 20177:15 amRNSHardman Research: Low response would be positive!
30th Jan 20177:00 amRNSDirector/PDMR Shareholding
20th Jan 201711:35 amRNSResult of Annual General Meeting
20th Jan 20177:00 amRNSTrading Update
11th Jan 20177:00 amRNSPresenting at London Growth and Innovation Forum
5th Jan 20177:00 amRNSDirector Dealing and Issue of Equity
20th Dec 20167:00 amRNSDirector/PDMR Shareholding
16th Dec 20165:14 pmRNSHolding(s) in Company
1st Dec 20167:00 amRNSNotice of AGM, Accounts and Directorate Change
23rd Nov 20167:00 amRNSTechnical Update: Affinity Separation
7th Nov 20167:00 amRNSCancer Expert joins Scientific Advisory Board
2nd Nov 20167:00 amRNSCAR-T Cell Therapy Research Collaboration in US
1st Nov 20167:00 amRNSResults from first Affimer pre-clinical studies
21st Oct 201611:39 amRNSDirector's Dealing
17th Oct 20161:00 pmRNSHardman Research: Great strides to strategic goals
17th Oct 20167:00 amRNSPrelim Results for the Year Ended 31 July 2016
4th Oct 20163:28 pmRNSIssue of Equity
26th Sep 201611:21 amRNSNotice of Results
22nd Sep 20167:00 amRNSPositive results from first preclinical studies
12th Sep 20167:00 amRNSChange of Adviser
31st Aug 20162:17 pmRNSChange of Registered Office
16th Aug 20167:00 amRNSNew Facilities in Cambridge and Wetherby
10th Aug 20167:00 amRNSGrant Funding
3rd Aug 20167:00 amRNSKey Affimer patents to be granted in Europe and US
1st Aug 20167:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.